Video Series

Panelists discuss how patients with recurrent urinary tract infections (UTIs) describe significant burdens including constant anxiety about symptom onset, disruption to work and social life, financial strain from frequent office visits and medications, frustration with treatment-resistant infections, embarrassment discussing symptoms, sexual dysfunction, relationship difficulties, and substantial mental health impacts such as depression and diminished quality of life.

Experts discuss the role of continuous glucose monitoring (CGM)-derived metrics, particularly glucose management indicator (GMI), in the new Healthcare Effectiveness Data and Information Set (HEDIS) diabetes care measures and ACO quality targets, and how CGM-specific metrics are being incorporated into the National Committee for Quality Assurance (NCQA)’s quality measures and the implications for health plans.

A panelist discusses how clinicians should systematically adopt evidence-based hidradenitis suppurativa (HS) guidelines while maintaining flexibility to tailor treatments to individual patient needs, severity levels, and comorbidities. This involves regular monitoring of updated recommendations, implementing standardized assessment tools, and considering patient-specific factors such as lifestyle, preferences, and treatment response history to optimize therapeutic outcomes through a personalized medicine approach.

Experts discuss what partnerships between academic and community settings look like with regard to bispecifics, highlighting the role academic centers play in supporting community practices with bispecific therapy protocols.

Experts discuss key payer-related challenges, such as step edits and prior authorizations, that impact access to third-line therapies for patients with metastatic colorectal cancer (mCRC). They also discuss how payer requirements influence treatment sequencing and decision-making in the third-line setting and how the costs associated with adverse events across different third-line treatments affect treatment selection.

Experts discuss how pharmacists contribute to managing adverse events and toxicity for patients undergoing metastatic colorectal cancer (mCRC) treatment. They explore the factors influencing patient adherence to third-line therapies and ways pharmacists can improve patient education to enhance adherence to treatment regimens.

Experts discuss the clinical and economic burden of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis in the US, exploring their impact on health care systems, the importance of prevention in reducing this burden, and the challenges of implementing preventive strategies, while considering the potential benefits of improved risk assessment and prevention in the ASCVD space.

Experts discuss atherosclerotic cardiovascular disease and aortic stenosis, as well as their burden, highlighting their prevalence, impact on patient health, and the growing need for effective management strategies.

Panelists discuss how selecting an optimal combination of screening assessments for Alzheimer disease requires careful consideration of test sensitivity, specificity, accessibility, cost-effectiveness, implementation feasibility, and alignment with patient populations and health care resource constraints.

Experts discuss the most common logistical challenges encountered when implementing bispecific therapies as well as the primary barriers smaller community practices face in operationalizing bispecific antibody treatments.

Experts discuss the relative value of different continuous glucose monitoring (CGM) metrics (glucose management indicator [GMI], time in range, glucose variability) in assessing glycemic control and how these outcomes vary across different patient populations.

Panelists discuss how significant knowledge gaps among nonspecialist providers—particularly regarding differential diagnosis, interpretation of cognitive assessments, and awareness of treatment options—are being addressed through targeted educational initiatives, embedded clinical decision support tools, and collaborative care models to enhance understanding of early Alzheimer diagnosis and treatment importance.

Experts discuss the clinical and practical factors that guide decision-making when recommending continuous glucose monitoring (CGM) vs traditional glucose monitoring for patients with type 2 diabetes.

Experts discuss the benefits of implementing and operationalizing bispecifics in the community oncology setting.

A panelist discusses how health system leaders should focus resources on implementing multidisciplinary care teams, standardizing staging/severity assessments, and ensuring access to recommended treatments outlined in current hidradenitis suppurativa (HS) guidelines. Priority areas include early diagnosis through provider education, establishing clear referral pathways to specialists, comprehensive symptom management including pain control, and tracking patient outcomes against quality metrics to improve care delivery and reduce disease burden.

Panelists discuss how uncomplicated urinary tract infection (UTI) recurrence affects 20% to 30% of female patients within 6 months of initial infection, with contributing factors including anatomical variances, hormonal changes, genetic predisposition, insufficient treatment duration, resistant pathogens, and biofilm formation that persists despite proper adherence to standard antibiotic protocols.

Experts discuss how the role of oncology pharmacists in managing metastatic colorectal cancer (mCRC) has evolved, particularly in enabling medication adjustments, refills, and prescribing supportive care medications, and explore the impact of this expanded role on patient outcomes and how pharmacists can leverage medication knowledge to optimize treatment and patient care further.

Experts discuss the typical patient journey for an individual with metastatic colorectal cancer (mCRC), highlighting where pharmacists participate in the process. They also explore how pharmacists collaborate with oncologists and other multidisciplinary team members to provide comprehensive care for patients with mCRC.

Panelists discuss how social determinants of health significantly influence uncomplicated urinary tract infection (UTI) prevalence and outcomes, with patients with lower income, those from rural areas, and those lacking consistent health care access experiencing higher infection rates, delayed treatment, increased complications, and poorer overall treatment success.

Panelists discuss how their practices have observed an increasing trend in uncomplicated urinary tract infections (UTIs), particularly among younger adult women and those with recurrent infections, noting potential contributing factors such as antibiotic resistance patterns and delayed care-seeking behaviors.

Panelists discuss how health care institutions have established structured care pathways for nonspecialist providers to evaluate mild cognitive impairment and mild dementia, incorporating validated questionnaires, standardized screening protocols, and clear referral guidelines to ensure consistent assessment across diverse clinical settings.

Panelists discuss how health care institutions employ comprehensive screening protocols for Alzheimer disease, including cognitive assessments, biomarker testing, and regular monitoring of at-risk populations, to facilitate early symptom identification and timely diagnosis that enables prompt intervention and improved patient outcomes.

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss how continuous glucose monitoring (CGM) adoption impacts clinical inertia and supports earlier therapeutic interventions across different patient populations, highlighting measurable improvements in patient outcomes, such as glycemic control, hemoglobin A1c (HbA1c) levels, hypoglycemic events, and quality of life.

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss the key benefits of continuous glucose monitoring (CGM) technology compared with traditional monitoring based on recent clinical trial data, including research on cardiovascular risk reduction in noninsulin-treated T2D.

Experts discuss which patient populations stand to benefit the most from recently approved bispecific therapies, identifying gaps or opportunities for further patient benefit, as well as the data gaps that exist in understanding the optimal use of bispecific antibodies across various cancer types.

Panelists discuss challenges oncologists face in managing treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), including balancing efficacy with adverse effect profiles, and highlight strategies such as multidisciplinary collaboration and access to updated treatment guidelines to address these issues while also expressing eagerness for future advancements in Bruton tyrosine kinase (BTK) inhibitors and the need for further research to refine treatment strategies and improve patient outcomes.

A panelist discusses how guidelines are important for knowing when patient care starts, the progress of the patients care, and if the patient is satisfied with the response. Treatment guidelines are available for the 3 stages of hidradenitis suppurativa (HS): Hurley 1, Hurley 2, and Hurley 3. High scar scoring is also used to examine improvement in scarring over time. In real-world cases, guidelines have little to no impact on physicians treating HS, and most people often go to urgent care centers or primary care physicians when they are experiencing symptoms of HS. Health providers do not utilize guidelines except in clinical trials.

Experts discuss how the availability of bispecific therapies has influenced treatment paradigms in oncology and how bispecifics fit into current treatment algorithms for hematologic malignancies and solid tumors.